day 2 agenda

Day -2(Sep 08, 2026)
Keynote Sessions
09:00-09:30	KeynoteTalk: GABA-A receptor modulating steroids enhance dementia, but antagonists inhibit inflammation and improve memory
	Torbjörn Bäckström, Umeå University, Sweden
09:30-10:00	Cortical neuron dysfunction in AD brain at early-stage without beta-amyloid aggregation
	Xiu-Ti Hu, Rush University Medical Center, USA
10:00-10:30	KeynoteTalk: Acetylcholinesterase inhibitors have anti- neurodegenerative benefits, but high-level CNS-selective acetylcholinesterase inhibition is needed for delaying the onset or preventing Alzheimer’s dementia
	Donald E. Moss, University of Texas at El Paso, USA
Group Photo & Refreshment Break (10:30-10:50)
Session Chair
Xiu-Ti Hu, USA
Technical session-III
Biomarkers for AD and Dementia, Basic and Translational Research & Genetics in Alzheimer’s and Dementia, Molecular and Cell Biology, Data Science and Artificial Intelligence
10:50-11:10	Long read sequencing in alzheimer’s disease and cerebral amyloid angiopathy
	Amanda J. Myers, University of Miami, USA
11:10-11:30	From Cost-Effective Plasma Biomarker Quantification to Cross-Cohort Machine Learning Translation in Alzheimer’s Disease
	Ebrahim Zandi, University of Southern California, USA
11:30-11:50	Towards a panel of seed amplification assays for the detection of protein pathologies in the CSF of living patients with dementia
	Magnus Macleod, University College London, UK
11:50-12:10	Slot Available
12:10-12:30	Exploring the role of Aβ-induced membrane damage in tau pathology
	Katherine R. Sadleir, , Northwestern University, USA
12:30-12:50	Development and Validation of Patient and Caregiver-Reported Outcome Measures for Alzheimer’s Disease, Mild Cognitive Impairment, and Dementia: The CI-HI & CICR-HI
	Charlotte Engebrecht, University of Rochester Center for Health + Technology, USA
12:50-13:10	Obtaining personalized predictions from a randomized controlled trial on Alzheimer’s disease
	Dennis Shen, University of Southern California, USA
13:10-13:30	Beyond Plaques and Tangles: Visualizing Early Oxidative Stress in Alzheimer's Disease via a Novel Radiotracer
	Meagan J McManus, University of Arizona, USA
Lunch Break @ Restaurant (13:30-14:10)
Session Chair
Guillermo A. Herrera, USA
Technical session-IV
Clinical Trials and Therapeutics & AD Drug Development and Animal Models
14:10-14:30	Transcranial Pulse Stimulation for early dementia: A Randomized, Sham-Controlled Safety and Efficacy Study
	Francesca Pistoia, University of L'Aquila, Italy
14:30-14:50	Personalizing Repetitive TMS in Major Depressive Disorder: An EEG?Based dlPFC Sensitivity Index Predicts Clinical and Cognitive Outcomes
	Li Wan, Anhui Medical University, USA
14:50-15:10	Proximity proteomics reveals distinct pE3-Aβ-associated networks in human Alzheimer’s disease hippocampus
	Alia O. Alia, Rush University Medical Center, USA
15:10-15:30	Slot Available
15:30-15:50	Federated Learning for Early Diagnosis of the Dementia
	Mohamed Elsersy, Higher Colleges of Technology, UAE
15:50-16:10	Tirzepatide Attenuates Neurotoxicity by Suppressing Inflammation, Apoptosis, and Restoring Neurotrophin Expression in an Alzheimer’s Disease-Like Rat Model
	Sabry Attia, King Saud University, Saudi Arabia
Refreshment Break(16:10-16:30)
Note: This is a Tentative program, subjects and timings will changes.
Day-2 Concludes

posters agenda

Day -1(Sep 07, 2026)
Virtual Tentative Program followed by CET
10:00-10:20	6-microRNA panel predicts amyloid-b status in cognitively normal older adults
	Joanna M. Williams, University of Otago, NewZealand
10:20-10:40	Development of amyloid β (1-42) certified reference material NMIJ CRM 6210-a
	Kazumi Saikusa, National Metrology Institute of Japan (NMIJ), Japan
10:40-11:00	Slot Available
11:00-11:20	Huntingtin’s N17 region: Post-translational modifications as modulators of protein self-association and membrane interaction
	Mariana Gallo, University of Parma, Italy
11:20-11:50	Keynote Talk: NAP, the investigational drug davunetide, from laboratory discovery to sex-specific cognitive protection in clinical trials
	Illana Gozes, Tel Aviv University, Israel
11:50-12:10	Selective manipulation of aging as a novel treatment for neurodegenerative disorders
	Ehud Cohen, The Hebrew University School of Medicine, Israel
12:10-12:30	Slot Available
12:30-12:50	Early Linguistic Indicators and Language-Focused Therapies in Alzheimer’s Disease
	Erika Smeriglio, University of Messina, Italy
12:50-13:10	Slot Available
13:10-13:30	Correction of the APP London (V717I) mutation using an optimized prime editing system.
	Jacques P. Tremblay, Université Laval, Canada
13:30-13:50	Methionine-sulfoxide based active immunization against Alzheimer’s disease
	Jackob Moskovitz, University of Kansas, USA
13:50-14:20	Keynote Talk: Elovanoids: linking nutrition to neuroprotection
	Nicolas G. Bazan, Neuroscience Center of Excellence, USA
14:20-14:40	Spiritual Fitness: The New Dimension In Alzheimer’s Disease Prevention
	Eve Adler, Alzheimer's Research and Prevention Foundation, USA
14:40-15:00	The importance of social relationships in place in Alzheimer’s Disease
	George Rook, a person living with dementia and co-researcher on several projects, USA
15:00-15:20	Slot Available
15:20-15:40	Establishing two-tier cutoffs for ptau217/A42 ratio in plasma for detection of Alzheimers disease pathology
	Leslie M Shaw, University of Pennsylvania, USA
15:40-16:00	Air pollution risk of Alzheimer in a mouse model of amyloidogenesis  is attenuated by modulation of gamma-secretase
	Caleb E Finch, University of Southern California, USA
Day-1 Concludes
Day -2(Sep 08, 2026)
Virtual Tentative Program followed by CET
10:00-10:20	Cultural Perspectives on Virtual delivery of Cognitive Stimulation Therapy for M?ori with Dementia (vCST-M?ori)
	Tai Kake, University of Auckland, NewZealand
10:20-10:40	The therapeutic potential of medicinal cannabis for neurodegenerative diseases – a preclinical perspective
	Tim Karl, Western Sydney University, Australia
10:40-11:00	Slot Available
11:00-11:20	Revitalizing Mitochondria against Alzheimer’s disease: The Synergistic Effects of a Nutraceutical Combination with urolithin A
	Dona Pamoda W. Jayatunga, University of Sri Jayewardenepura, Sri Lanka
11:20-11:50	Keynote Talk: Restoring neuronal function by restoring the septin cytoskeleton
	Gerard Griffioen, remynd, Belgium
11:50-12:10	Targeting the GSK3β/Nav1.6 protein–protein interaction offers a promising new therapeutic approach for early-stage Alzheimer’s disease
	Fernanda Laezza, University of Texas Medical Branch, USA
12:10-12:30	Non-catalyzed covalent dimerization of amyloid b and implications for Alzheimer’s disease
	Suren A. Tatulian, University of Central Florida, USA
12:30-12:50	Protein disulfide isomerase dissolves and detoxifies oligomeric assemblies of amyloid beta peptide
	Ken Teter, University of Central Florida, USA
12:50-13:10	Molecular Mechanisms Underlying the Inverse Roles of Heme Function in Lung Cancer and Alzheimer’s Disease
	Li Zhang, University of Texas at Dallas, USA
13:10-13:30	Slot Available
13:30-13:50	Alzheimer’s Is Dynamic – Our Language Has Not Kept Pace: Redefining Diagnosis Through Precision and Human-Centered Staging
	Lauren P. Brown, The Alzheimer's Experience, USA
13:50-14:20	Keynote Talk: Systems Thinking
	Michael Fossel, Michigan State University, USA
14:20-14:40	Identification of novel shared antibodies and infectious disease associations in Alzheimer’s disease
	Mark Hicar, University at Buffalo, USA
14:40-15:00	Slot Available
15:00-15:20	Asymmetric Cerebral Hypoperfusion Drives Regional Blood Brain Barrier Permeability in a Vascular Dementia Model
	Zhen Xu, The University of Texas Health Science Center at Houston, USA

The program for this session is currently being updated to accommodate recently received abstracts and ongoing scientific scheduling.
Full session details will be announced soon.